Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Takatsugu Ogata

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Ogata1, H. Satake2, M. Ogata1, Y. Hatachi1, M. Hamada3, H. Yasui1

Author affiliations

  • 1 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 2 Cancer Treatment Center, Kansai Medical University Hospital, 5731191 - Hirakata/JP
  • 3 Department Of Surgery, Kansai Medical University Hospital, 5731191 - Hirakata/JP
More

Resources

Background

The TRIBE study showed that FOLFOXIRI plus bevacizumab therapy is an effective treatment for metastatic colorectal cancer (mCRC). This study aimed to determine the safety and effectiveness of FOLFOXIRI therapy as a first-line treatment.

Methods

We retrospectively collected data of patients with mCRC treated with FOLFOXIRI from March 2014 to December 2017 in two centres.

Results

Fifty-five patients were enrolled in this study (median age, 60 years; males 25, females 30). The tumour location was classified as right and left in 15 and 40 patients, respectively. Twenty-nine and twenty-six patients had RAS wild-type disease and mutation-type disease, respectively. Anti-VEGF and anti-EGFR antibodies were used in 38 and 17 patients, respectively. The most common grade 3 or 4 adverse event was neutropenia (51%). Skin toxicities and hypomagnesaemia showed a statistically higher frequency among patients with anti-EGFR antibodies (P < 0.001 and P = 0.039, respectively). The overall response rate (ORR) was 67% (complete response [CR], 7 patients; partial response [PR], 30 patients; not evaluated [NE], 1 patient), and the disease control rate was 96% (stable disease, 16 patients). The median progression free survival (mPFS) was 11.0 (0.43 − 45.3) months and the median overall survival (mOS) was 41.9 (1.00 − 45.3) months. In FOLFOXIRI plus anti-VEGF antibodies, the ORR was 55% (CR, 5 patients; PR 16 patients), and in FOLFOXIRI plus anti-EGFR antibodies, the ORR was 94% (CR, 2 patients; PR, 14 patients; NE, 1 patient) (P = 0.271). With a median follow up of 18.4 months, mPFS and mOS were not significantly different in patients with anti-EGFR antibodies or anti-VEGF antibodies (hazard ratio [HR], 3.12 [0.883 − 11.0]; P = 0.143 and P = 0.063, respectively). Twelve patients had progressive disease (PD) during the induction phase. In these patients, mOS was significantly poorer (13.2 months versus 41.9 months; HR, 23.3 [6.77 − 80.1]; P < 0.001).

Conclusions

FOLFOXIRI plus molecular target therapy showed impressive results for patients with mCRC. The response rate was significantly higher in patients with anti-EGFR antibodies, although skin toxicities and hypomagnesaemia tend to occur in these patients.

Clinical trial identification

Legal entity responsible for the study

Kobe City Medical Center General Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?

Presenter: Shinsuke Nagasawa

Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Resources:

Abstract

Utility of Carcinoembryonic Antigen (CEA) in Appendiceal carcinoma

Presenter: ASHA KARIPPOT

Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings